Fast Five Quiz: HER2+ Breast Cancer

Pavani Chalasani, MD, MPH


August 23, 2022

In the phase 3 EMILIA study, ado-trastuzumab was associated with significantly prolonged progression-free survival and overall survival than lapatinib and capecitabine in patients with advanced HER2+ breast cancer who had previously received trastuzumab and a taxane.

The tyrosine kinase inhibitor tucatinib in combination with trastuzumab and capecitabine has been shown to improve survival in patients with metastatic HER2+ breast cancer, including those with brain metastases. In the HER2CLIMB trial, progression-free survival and overall survival were extended among heavily pretreated patients in this population who received trastuzumab and capecitabine plus tucatinib vs trastuzumab and capecitabine plus placebo.

Pertuzumab has been shown to have efficacy in both the adjuvant and the neoadjuvant settings. In the APHINITY trial, pertuzumab in combination with trastuzumab and docetaxel was associated with improvements in survival and disease recurrence.

According to the ESMO Clinical Practice Guideline for the diagnosis, staging, and treatment of patients with metastatic breast cancer, patients who have progressed on an anti-HER2 therapy combined with a cytotoxic or endocrine agent should be offered additional anti-HER2 therapy with subsequent treatment, unless contraindicated, because continued suppression of the HER2 pathway is beneficial.

Learn more about the treatment of HER2+ breast cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.